Nymox Pharmaceutical Corp (NYMX.OQ)
|Market Cap (Mil.):||$176.65|
|Shares Outstanding (Mil.):||35.40|
- Nymox Pharmaceutical Corp said its experimental prostate cancer drug reduced the progression of cancer in patients, but it could not determine if the study succeeded in meeting pre-determined goals due to a high rate of incorrect biopsies.
April 30 - Nymox Pharmaceutical Corp said its experimental prostate cancer drug reduced the progression of cancer in patients, but it could not determine if the study succeeded in meeting pre-determined goals due to a high rate of incorrect biopsies.
|Siemens AG (SIEGn.DE)||€90.66||-0.97|
|Johnson & Johnson (JNJ.N)||$103.13||+0.50|
|Pfizer Inc. (PFE.N)||$29.11||+0.51|
|Novartis AG (NOVN.VX)||CHF85.75||+0.35|
|Merck & Co., Inc. (MRK.N)||$57.61||+0.98|
|Roche Holding Ltd. (ROG.VX)||CHF278.00||-1.40|
|Abbott Laboratories (ABT.N)||$42.46||+0.03|
|AstraZeneca plc (AZN.L)||4,327.50p||-7.00|
|Eli Lilly and Co (LLY.N)||$66.05||+1.70|
|Bristol-Myers Squibb Co (BMY.N)||$53.63||+1.13|
Earnings vs. Estimates
Analyst Research Reports
Provider: New Constructs, LLC
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of NYMOX PHARMACEUTICAL CORP including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: Thomson Reuters Stock Report
Provider: S&P Capital IQ Factual Report
Provider: Pechala's Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.